Search PubMed⌕ Search

Biomedical subjects

A Sugitachi

Publications and source records attributed to A Sugitachi.

34 records · Page 2Linked to original sources
PubMed1983

Preoperative transcatheter arterial chemo-embolization for locally advanced breast cancer. Application of new thrombotic materials.

The anticancer drugs, Adriamycin and Mitomycin were individually immobilized on absorbable gelatin materials, together with a blood clotting factor, Factor XIII and thrombin, using a special technique. The materials were applied as thrombotic agents in preoperative therapeutic transcatheter arterial embolization for patients with locally advanced breast cancer. This approach to preoperative management proved to be superior to intra-arterial infusion therapy currently applied in various clinics.

Adult↗
PubMed1983

[Pre-operative transcatheter arterial embolization for the patients with locally advanced breast cancers--a newly deviced thrombotic material].

Anticancer agents, Mitomycin C and Adriamycin, were immobilized on absorbable gelatin materials, respectively with a blood clotting factor, Factor XIII and thrombin with a special technique we have developed. The materials were clinically applied as thrombotic agent in pre-operative therapeutic transcatheter arterial embolization (TAE) to 5 patients with locally advanced breast cancer. About 1 week after TAE, the regression of the primary tumor was found in 4 out of 5 patients; all patients received currative operation without any trouble. The histological examinations of the excised specimens showed remarkable degenerative changes (IIA and IIB: Shimosato's classification) of cancer cells not only in the primary tumor, but also in the metastatic regional lymph node. No complications due to the TAE were observed. These findings strongly suggest that this newly deviced materials are quite effective in pre-operative treatment for the locally advanced breast cancers.

Antibiotics, Antineoplastic↗
PubMed1978

Immobilization of plasminogen activator, urokinase, on nylon.

Urokinase (UK), a fibrinolytic enzyme activator purified from human material was immobilized on nylon using different procedures. One was a modified method of immobilization of antigen or antibody initially carried out by Edelman and others in 1971 (Procedure I). The other was our newly devised method (Procedure II) (Sugitachi et al. 1976). Major specificities of the immobilized UK are as follows: 1. The UK revealed properties of a plasminogen activator and the optimum pH of the immobilized UK was between 7.2 and 7.4, these values being in good parallel with that of soluble UK. The immobilized UK maintained a stable fibrinolytic activity after long-term preservation and heat-treatment. 2. As the fibrinolytic activity of immobilized UK was found to be inhibited by the antiplasmin in human plasma, an antiplasmin inhibitor was immobilized on the nylon together with the UK. The antiplasmin activity was to some extent prevented using this procedure. 3. Nylon tubes immobilized with UK and antiplasmin inhibitor were used for thrombotic coagulation studies carried out according to the method of Chandler. Thrombus formation time (TFT) of UK-immobilized tubes was 30 min, while that of the non-treated tubes was no longer than 10 min.

Antifibrinolytic Agents↗
PubMed1978

Antithrombogenicity of immobilized urokinase--clinical application.

A plasminogen activator, urokinase (UK) was immobilized on four different polymer surfaces: nylon, silicone rubber, poly (vinyl chloride) and a polyester, using our newly devised technique. Each material proved to have plasminogen activating activity. In vitro the thrombus formation time (TFT) of the UK-immobilized nylon tubes was over 45 minutes and the TFT of UK-immobilized silicone rubber tubes varied. When applied clinically, the UK-immobilized nylon tubes showed excellent antithrombogenicity.

Biocompatible Materials↗
PubMedDate not supplied

Combined transcatheter arterial embolization and regional chemotherapy for locally advanced carcinoma of the breast. A preliminary investigation.

Seventeen patients with carcinoma of the breast received a combination of transcatheter arterial embolization and regional chemotherapy before surgery. A gelatin powder mixed with an anticancer agent and blood clotting factors (own technique) was selectively injected into the internal mammary artery, the lateral thoracic artery, and the thoracodorsal artery. Marked regression of both primary tumor and metastatic regional lymph nodes was observed. The potential of this method as presurgical treatment is discussed.

Adult↗
PubMedDate not supplied

A newly designed anticancer tumor immunity drug delivery system.

The authors used a fibrin clot (FC) as a carrier of an anti-cancer drug (AD) to achieve sustained release of the drug. Adriamycin (ADM) and cis-platinum (CDDP) were individually encapsulated into an FC, and the profile of release of each AD from the FC-AD was examined in vitro. The FC-AD was placed intra-abdominally in ascites hepatoma AH130-bearing rats, and ADM or CDDP solution was intraperitoneally injected (IP) into other cancer bearing rats. The survival time was recorded, and related oncolytic mechanisms were investigated. The release of AD from the FC continued for over 15 days. Sixty-eight percent of the rats treated with FC-AD survived for more than 200 days and evidence of malignancy disappeared. Almost all of the IP rats and non-treated rats died within 20 days; these animals had massive ascites and extensive metastases. Immunologic studies confirmed that various tumor immunoresponses were induced in the rats treated with FC-AD. The FC-AD system warrants further study for possible antineoplastic activities in vivo.

Animals↗